Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03912350
Recruitment Status : Not yet recruiting
First Posted : April 11, 2019
Last Update Posted : October 8, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared to healthy subjects with normal hepatic function matched by age (±10 years), sex, and body mass index (BMI; ±20%).

Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Drug: Balovaptan Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan: A Phase I, Multiple-Center, Open-Label Study Following Multiple Daily Oral Doses of Balovaptan in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function
Estimated Study Start Date : March 1, 2020
Estimated Primary Completion Date : September 24, 2020
Estimated Study Completion Date : October 13, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Test group
Participants with moderate hepatic impairment.
Drug: Balovaptan
Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.

Active Comparator: Reference group
Healthy pariticipants with normal hepatic function.
Drug: Balovaptan
Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.




Primary Outcome Measures :
  1. Plasma concentration of balovaptan [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16 hours post-dose on Day 1; pre-dose on Day 2 to Day 13; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  2. Plasma concentration of M2 metabolite, as applicable [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16 hours post-dose on Day 1; pre-dose on Day 2 to Day 13; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  3. Plasma concentration of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16 hours post-dose on Day 1; pre-dose on Day 2 to Day 13; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  4. AUC during the dosing interval on Day 1 of balovaptan [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1 ]
  5. AUC during the dosing interval on Day 1 of M2 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1 ]
  6. AUC during the dosing interval on Day 1 of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1 ]
  7. AUC during the dosing interval at steady state on Day 14 of balovaptan [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  8. AUC during the dosing interval at steady state on Day 14 of M2 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  9. AUC during the dosing interval at steady state on Day 14 of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  10. Maximum observed plasma concentration (Cmax) of balovaptan [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  11. Maximum observed plasma concentration (Cmax) of M2 metabolite [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  12. Maximum observed plasma concentration (Cmax) of M3 metabolite [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  13. Time of maximum observed plasma concentration (Tmax) of balovaptan [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  14. Time of maximum observed plasma concentration (Tmax) of M2 metabolite [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  15. Time of maximum observed plasma concentration (Tmax) of M3 metabolite [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  16. Metabolite:Parent ratio of area under the plasma (MRauc) of M2 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  17. Metabolite:Parent ratio of area under the plasma (MRauc) of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  18. Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M2 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  19. Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  20. Apparent volume of distribution (V/F) of balovaptan [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  21. Apparent volume of distribution (V/F) of M2 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  22. Apparent volume of distribution (V/F) of M3 metabolite [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  23. Terminal phase rate constant (λZ) of balovaptan, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  24. Terminal phase rate constant (λZ) of M2 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  25. Terminal phase rate constant (λZ) of M3 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  26. Apparent terminal elimination half-life (t½) of balovaptan, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  27. Apparent terminal elimination half-life (t½) of M2 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  28. Apparent terminal elimination half-life (t½) of M3 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  29. Apparent plasma clearance after oral administration (CLss/F) of balovaptan, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  30. Apparent plasma clearance after oral administration (CLss/F) of M2 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  31. Apparent plasma clearance after oral administration (CLss/F) of M3 metabolite, when possible [ Time Frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  32. Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of balovaptan, when possible [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  33. Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M2 metabolite, when possible [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]
  34. Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M3 metabolite, when possible [ Time Frame: 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 1; pre-dose and 1, 2, 3, 4, 5, 6, 9, 12, 16, and 24 hours post-dose on Day 14 ]

Secondary Outcome Measures :
  1. Percentage of participants with adverse events [ Time Frame: Up to approximately 18 weeks from screening (screening is up to 28 days prior to admission to the clinical research unit). ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for All Participants:

  • BMI between 18 and 40 kg/m2, inclusive.
  • Women of childbearing potential must either: agree to use one highly effective contraceptive method combined with a barrier method from Screening until 90 days after the last dose of study drug or practice true abstinence because of the subject's lifestyle choice; be in an exclusively same-sex relationship.
  • For men: agreement to use contraceptive measures
  • Females of child-bearing potential must refrain from donating ova from Day -1 until 90 days after the safety Follow-up visit. Males must refrain from donating sperm from Day -1 until 90 days after the safety Follow-up visit.

Inclusion Criteria for Participants with Hepatic Impairment:

  • Stable, documented moderate liver disease diagnosed >6 months and stable for at least 3 months prior to Screening.
  • Participants with moderate hepatic impairment may have medical findings consistent with their hepatic dysfunction. Participants with abnormal findings considered in line with underlying hepatic disease by the Investigator will be eligible.

Inclusion Criteria for Healthy Participants:

  • Healthy status is defined by no clinically significant findings from medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, chemistry, and urinalysis at Screening and/or Day -1 as assessed by the Investigator (or designee). Gilbert's syndrome is acceptable.

Exclusion Criteria for All Participants:

  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, constituents or excipients of the study drug, food, or other substance, unless approved by the Investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  • Evidence of hepatorenal syndrome and estimated creatinine clearance range <60 mL/min or abnormal and clinically significant sodium and potassium levels, as determined by the Investigator (or designee).
  • Female subjects of childbearing potential with a positive serum pregnancy test at Screening and/or at admission (Day -1), or who are lactating.
  • History of drug/chemical abuse within 2 years prior to Screening; current active substance abuse will not be permitted.
  • Known personal or family history of congenital long QT syndrome or sudden unexplained death.

Exclusion Criteria for Participants with Hepatic Impairment:

  • History within 3 months prior to Screening, or current symptoms of, hepatic encephalopathy Grade 2 and above.
  • Evidence of severe ascites.
  • Recent history of, or the treatment of, esophageal bleeding within 3 months of first dose, unless banded.
  • Participants who have had a porto-systemic shunt.
  • Participants who have a history of paracentesis within 3 months prior to Day -1.
  • Participants who have a history of unstable diabetes mellitus as evidenced by hemoglobin A1c ≥ 9% at Screening.
  • History of alcoholism within 3 months prior to Screening.
  • Use of any prescription drugs within 30 days (or within 5 times the elimination half-life, if known, of the medication, whichever is longer) of first dose, with the exception of therapies for hepatic-associated disorders that have been stable for at least 60 days prior to first dose.
  • Biliary liver cirrhosis or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
  • Positive result on human immunodeficiency virus (HIV) 1, HIV2, Hepatitis B Surface Antigen (HBsAg).

Exclusion Criteria for Healthy Participants:

  • History of presence of liver disease, injury, or dysfunction as indicated by any clinically significant deviations from normal reference ranges in liver function tests, unless approved by the Investigator of designee.
  • Participants likely to need prescription medication during the study. Participants who have received any prescribed systemic or topical medication within 30 days (or within 5 times the elimination half-life, if known, of the medication, whichever is longer) of the first dose administration, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
  • Any slow-release medicinal formulations considered to still be active within 4 weeks (or within 5 times the elimination half-life of the medication, whichever is longer) prior to the first study drug administration are prohibited, unless in the opinion of the Investigator or designee the medication will not interfere with the study procedures or compromise safety.
  • History of alcoholism within 2 years prior to Screening.
  • Positive result on HIV 1, HIV2, HBsAg, Hepatitis B core antibody (HBcAb), and/or HCV antibody.
  • Signs and symptoms potentially indicative of peripheral neuropathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03912350


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: WP41045 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

Locations
Layout table for location information
United States, Florida
Clinical Pharmacology of Miami, Inc. Not yet recruiting
Miami, Florida, United States, 33014
Orlando Clinical Research Center Not yet recruiting
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03912350     History of Changes
Other Study ID Numbers: WP41045
First Posted: April 11, 2019    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders